Loading...
XNAS
GERN
Market cap1.00bUSD
Jul 09, Last price  
1.56USD
1D
0.00%
1Q
-6.59%
Jan 2017
-24.64%
Name

Geron Corp

Chart & Performance

D1W1MN
XNAS:GERN chart
P/E
—
P/S
5.44
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.69%
Rev. gr., 5y
273.49%
Revenues
184m
+138.83%
3,277,0007,622,0002,803,0001,726,0003,563,0002,438,0002,709,0001,283,0001,153,00036,371,0006,162,0001,065,0001,066,000460,000253,0001,393,000596,000237,00076,994,000183,881,000
Net income
-86m
L-50.86%
-31,365,000-36,697,000-62,021,000-70,184,000-111,377,000-96,853,000-68,881,000-38,379,000-35,670,00046,000-29,537,000-27,916,000-27,017,000-68,548,000-75,617,000-116,112,000-141,901,000-184,127,000-174,572,000-85,782,000
CFO
-111m
L-49.21%
-26,379,000-26,632,000-41,985,000-43,374,000-44,292,000-62,392,000-55,146,000-36,680,0009,350,000-24,196,000-18,369,000-20,556,000-21,009,000-43,829,000-66,652,000-95,556,000-127,379,000-167,743,000-218,618,000-111,037,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
URL
https://www.geron.com/
IPO date
Jul 31, 1996
Employees
107
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT